menu
    • menu
    [{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ Moleculin Biotech"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab tesirine-lpyl","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sterling Pharma Solutions \/ Sterling Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Sterling Pharma Solutions \/ Sterling Pharma Solutions"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Oxaliplatin","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ OncoTEX","highestDevelopmentStatusID":"4","companyTruncated":"Sterling Pharma Solutions \/ OncoTEX"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Hypericin Sodium","moa":"","graph1":null,"graph2":null,"graph3":"Sterling Pharma Solutions","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ Soligenix","highestDevelopmentStatusID":null,"companyTruncated":"Sterling Pharma Solutions \/ Soligenix"}]

    Find Clinical Drug Pipeline Developments & Deals by Sterling Pharma Solutions

    Menu

    Sterling Pharma Solutions

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hypericin Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Soligenix Announces Partnership with Sterling Pharma Solutions

                            Details : The partnership aims to implement a commercially viable, scalable production technology for synthetic hypericin, the active ingredient in HyBryte and SGX302 being developed for CTCL and psoriasis.

                            Brand Name : HyBryte

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : Hypericin Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : OncoTEX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            OncoTEX and Sterling Pharma Solutions Sign Clinical Manufacturing Agreement for the Development of Novel Treat...

                            Details : OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers. Under the terms of the agreement, Sterling will produce clinical material in its cGMP facility in Germantown, Wisconsin.

                            Brand Name : OxaliTEX

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : Oxaliplatin,Texaphryn

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : OncoTEX

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Loncastuximab tesirine-lpyl

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : ADC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ADC Therapeutics’ ZYNLONTA Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in ...

                            Details : The NCCN Guidelines now include ZYNLONTA as a category 2A designation as a treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

                            Brand Name : Zynlonta

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 05, 2021

                            Lead Product(s) : Loncastuximab tesirine-lpyl

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : ADC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed

                            Sterling Pharma Solutions

                            United Kingdom arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WP1122

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Moleculin Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Dr...

                            Details : Moleculin Biotech has signed an agreement with Sterling Pharma for US production of WP1122 to support its expanded development efforts in preparation for submitting a request to the US FDA for Investigational New Drug status for WP1122 for the potential ...

                            Brand Name : WP1122

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 15, 2020

                            Lead Product(s) : WP1122

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Moleculin Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth